OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VNRX
VolitionRx Limited
There isn't enough reported data to score VNRX yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VNRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
VNRX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
VNRX PE Valuation
VNRX has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
VNRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect VNRX's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over VNRX on earnings quality, reporting a profit while its opponent remains loss making.
VNRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.00 | +$1.81 |
| Q2 2026 | -$3.79 | +$1.27 |
| Q1 2026 | -$4.14 | +$1.24 |
| Q4 2025 | -$4.37 | +$1.83 |
| Q3 2022 | -$11.48 | -$2.48 |
| Q2 2022 | -$11.37 | -$3.17 |
| Q1 2022 | -$10.67 | -$2.07 |
| Q4 2021 | -$10.20 | -$1.20 |
VNRX is still losing money, but far less than before: $3.00 per share over the past year, against $11.48 at its worst in late 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over VNRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over VNRX on profitability, with a higher operating margin.
VNRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | +157% |
| Q2 2026 | $398.7K | -2% |
| Q1 2026 | $985.1K | +300% |
| Q4 2025 | $447K | +133% |
| Q3 2025 | $627.3K | +32% |
| Q2 2025 | $406.7K | +2.8% |
| Q1 2025 | $246.4K | +44% |
| Q4 2024 | $191.7K | -21% |
VNRX's revenue is growing: $2M last quarter, up 157% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -207% | +607 points |
| Q2 2026 | -1043% | +506 points |
| Q1 2026 | -543% | +1698 points |
| Q4 2025 | -1078% | +1939 points |
| Q3 2025 | -813% | +424 points |
| Q2 2025 | -1549% | +218 points |
| Q1 2025 | -2241% | +2647 points |
| Q4 2024 | -3017% | +566 points |
VNRX's operating margin was −207% last quarter, up 607 points from the same quarter a year ago, near the top of its range since 2020.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over VNRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
VNRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.6M | -$1M |
| Q2 2026 | -$5.2M | +$1.2M |
| Q1 2026 | -$5.3M | -$989.5K |
| Q4 2025 | -$5.5M | +$1.5K |
| Q3 2025 | -$3.6M | +$1.9M |
| Q2 2025 | -$6.3M | +$431.9K |
| Q1 2025 | -$4.3M | +$4.1M |
| Q4 2024 | -$5.5M | -190% |
VNRX has burned cash in almost every quarter: −$21M over the past year, against −$20M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over VNRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VNRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +106% | +9.7M shares |
| 1 year | +249% | +13.5M shares |
| 3 years | +380% | +15M shares |
| 5 years | +611% | +16.2M shares |
| Available history | +865% | +16.9M shares |
VNRX has 19M diluted shares, up 249% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $31,772 |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
VNRX Net Leverage
VNRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VNRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 4.8 | Oversold |
VNRX's weekly RSI is 24 (oversold) and its Stochastic is 5 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VNRX PE vs Healthcare Sector
VNRX has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over VNRX on trend strength, trading above more of its moving averages.
VNRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.20 | 10% below |
| 20 week MA | $0.52 | 65% below |
| 50 week MA | $2.51 | 93% below |
| 100 week MA | $7.06 | 97% below |
| 200 week MA | $14.3 | 99% below |
VNRX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VNRX on returns for 2026, with the stronger performance.
VNRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.0 | $86.6 | -5.9% |
| 2021 | $86.6 | $64.8 | -25% |
| 2022 | $64.8 | $49.0 | -24% |
| 2023 | $49.0 | $14.3 | -71% |
| 2024 | $14.3 | $12.3 | -14% |
| 2025 | $12.3 | $5.00 | -59% |
| 2026 YTD | $5.00 | $0.18 | -96% |
VNRX has finished every year since 2020 lower, and it's down 96% so far in 2026.